Pre-Conference Workshop Day
Tuesday, February 22 | 9:00am - 5:30pm EST

8.30 | Opening Registration & Morning Coffee

9:00am | Workshop A

Harnessing Cancers Adaptive Resistance Profiles – Streamlining the Discovery of Novel Targeted Drugs Against RAS Cancers That Overcome Treatment Resistance

Through mimicking a native tumor micro-environment and treatment over months, resistanceBio can develop clinically relevant cancer resistance models without genetic manipulation. Despite significant successes in developing targeted therapies against RAS-driven cancers, genomic and non-genomic resistance mechanisms remain the fundamental challenge in discovering and developing anti-RAS treatments. Harnessing the novel pathways and targets differentially expressed or regulated due to cancer adaptation to treatment is critical to overcoming resistance. With resistanceBio proprietary resistance culturing system, ResCu, and by leveraging integrated multi-omic single cell measurements, it is possible to discover and develop targeted therapies that adapt to tumor resistance profiles throughout treatment.

In this session, we will consider:

  • How to fundamentally change the patient outcome by uncovering critical tumor adaptation information and understand how this will change throughout treatment
  • How to leverage adaptive tumor profiles to discover better drugs that can overcome resistance
  • The potential effects of a streamlined discovery process to discover treatments that can overcome cancers adaptive resistance
Nick Goldner, Resistance Bio

Nicholas Goldner
Chief Executive Officer
Co-Founder at ResistanceBio

11:00am | Structured Networking & Refreshment Break

As the RAS community is reunited, this valuable session will ensure you can reconnect with your peers in the room to make new and lasting connections. Running concurrently as an in-person and digital session, all attendees will have the opportunity to meet and network with their academic and industry colleagues

11:30am | Workshop B

Understanding Membrane Bound RAS Molecules – Lipid Interactions & Sorting Mechanisms as a RAS Signalling Platform

It is understood that RAS proteins are mainly localized to the plasma membrane and that their function is influenced by sorting mechanisms in the membrane. Thus, it is not surprising that this membrane based platform has a significant role to play in the downstream regulation of RAS cell-signalling. It is critical that we understand how RAS proteins locate and interact with different membrane properties, in order to discover strategies for targeting and modulating the downstream signalling cascade. In this workshop we will review the known literature and consider how this may guide future discovery of RAS-targeted therapies.

In this session, we will consider:

  • Review the literature outlining how RAS localisation and its sorting at the membrane are critical for downstream RAS cell signalling
  • Strategies on how the interaction of Ras with membranes can be studied in diverse experimental setups
  • How this information can guide future efforts and discovery of RAS-based therapies
Tommy Turbeyville, NIC

Tommy Turbyville
Principal Scientist, RAS Imaging and Assays, RAS Initiative
Frederick National Laboratory for Cancer Research

Rebika Shrestha, NIH

Rebika Shrestha
Scientist I, RAS Imaging and Assays, RAS Initiative
Frederick National Laboratory for Cancer Research

1:00pm | Lunch & Networking Break

2:00pm | Workshop C

Computational Methods & AI - Making Undruggable Targets Druggable?

Recently novel computational techniques combined with an unprecedented accessibility to significant computational power have allowed for computationally driven breakthroughs in many fields. The ability of novel ML driven methods to achieve superhuman results and match or outperform experimental methods has now been demonstrated. Undruggable targets, like non-G12C mutant KRAS, present a data poor environment and are a challenge to current methods. Novel computational techniques are emerging to address this challenge and may lead to a breakthrough in drug discovery. Join us as we discuss where we are, what can and can’t be done today, and what is in the pipeline for the near future.

In this session, we will consider:

  • The current computational techniques and how are these being employed to reach undruggable targets
  • What are the current challenges, and limitation of harnessing computational methods and AI for experimental data?
  • The future potential of computational techniques in reaching novel targets beyond G12C
Marcel Frenkel, ten63

Marcel Frenkel
Chief Executive Officer
Ten63 Therapeutics

Mark Hallen CTo

Mark Hallen
Chief Technology Officer
Ten63 Therapeutics

3:30pm | Afternoon Refreshment & Networking Break

4:00pm | Workshop D

Leveraging Tumor Microenvironment & Tumor Cell Dependency in RAS-Driven Tumors

It has been long understood that RAS-mutated tumors have significant effects altering the local tissue environment and drive tumor-cell dependency. There are various treatments that have been explored, such
as immune checkpoint blockade, whereby targeting the tumor microenvironment to impair cancer progression became a significant therapeutic option. Despite ongoing work, there remain challenges and mechanisms to uncover, as the industry continues to unveil taumor cell intrinsic mechanisms, how microphages within the microenvironment play an important role to support the tumor cells to bypass RAS tumor-cell dependency and much more. This workshop will delve into the ongoing efforts to uncover the interplay between tumor microenvironment and RAS driven cancers.

In this session, we will consider:

  • Reviewing data and experimental studies uncovering critical insights into RAS-tumor microenvironment
  • How immune based therapies are leveraging the tumor microenvironment and tumor-cell dependency to discovery anti-RAS drugs
  • The future potential and applicability of immune based therapies for single agent and combination therapies
Trever Bivona, UCSF

Trever Bivona
Professor, Hematology & Oncology

Erik knelson, Dana Farber

Erik Knelson
Medical Oncologist
Dana-Farber Cancer Institute


Carmine Fedele
Principal Scientist II, Oncology-Drug Discovery
Novartis Institute of Biomedical Research

5:30pm | End of Pre-Conference Workshop Day